Drug Profile

GS 8823

Alternative Names: 5T4 ADC - Tubulis; GS-8823; TUB-030

Latest Information Update: 01 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tubulis
Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

21 May 2026 Tubulis has been acquired by Gilead Sciences
13 Dec 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06657222)
24 Oct 2024 Tubulis plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in the USA (IV, Infusion) in December 2024 (NCT06657222)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com